Three billion dollars into Altos Labs. Calico working in near-silence for over a decade. Loyal running drug trials in dogs. Bryan Johnson publishing his bloodwork in public. A field that used to live at the edges of biology has moved, almost without announcement, into the center of serious science and serious capital — and most people still haven't noticed.
For most of the twentieth century, the study of aging was a quiet academic backwater. The assumption, rarely questioned, was that decline was simply the cost of time: a one-directional process to be endured rather than understood. The interesting biology happened elsewhere — in cancer, in cardiology, in the immune system. Aging was the weather, not the subject.
What changed was not a single discovery but an accumulation. The recognition that the hallmarks of aging — cellular senescence, mitochondrial decline, the slow erosion of proteostasis — are not random misfortunes but measurable, and in some cases reversible, processes. Once a thing can be measured, it can be targeted. And once it can be targeted, it attracts the people who build companies.
A field that used to ask why we age now asks a far more dangerous question: what happens if we don't have to.
The result is an industry still defining its own edges. On one side sit the moonshots — the reprogramming labs, the partial-rejuvenation bets, the work measured in decades. On the other sit the practical interventions available today: the compounds with real human data, the protocols a careful person can actually follow. The distance between these two poles is the whole story.
It is easy to be cynical here, and much of the cynicism is earned. The space is crowded with overpromising, with supplements sold on the strength of a single mouse study, with the familiar machinery of hope dressed up as science. Restraint is rare precisely because it is unprofitable.
But to dismiss the entire field on the strength of its worst actors is its own kind of error. The serious work is real, and it is advancing. The task — for a company and for a reader — is to stand in the narrow space between credulity and contempt, and to take the genuinely-supported seriously without mistaking it for magic.
— ReHuman System
